Observational studyEuropean journal of pediatrics2026
Listeria monocytogenes meningitis beyond the neonatal period: a multicenter case series of previously unpublished pediatric cases from Türkiye.
Observational study in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric Listeria monocytogenes meningitis beyond the neonatal period is rare and poorly characterized; we aimed to describe previously unpublished cases from Türkiye. In this multicenter retrospective case series (2015-2025), children 1 month-18 years with compatible clinical and cerebrospinal fluid (CSF) findings and microbiologically confirmed L. monocytogenes meningitis (CSF culture/PCR or blood culture with compatible CSF findings) were included. Previously published or concurrently submitted cases were excluded. Outcomes were assessed using the Glasgow Outcome Scale (GOS). Eleven previously unpublished patients (6 M/5F; median age 49 months, IQR 15.5-74.5) were included. CSF culture was positive in 10/11 (90.9%); CSF PCR was performed in 9 patients and confirmed the diagnosis in all, including one with negative culture. Blood cultures were positive in 3/11 (27.3%). Fever, altered consciousness (90.9%), and meningeal signs (81.8%) predominated. Four (36.4%) had immune-related conditions: MHC class I deficiency, T-cell acute lymphoblastic leukemia, juvenile dermatomyositis on immunosuppression, and Crohn disease; six (54.5%) had no underlying disorder, and one had a non-immune condition (osteogenesis imperfecta). Ampicillin-based therapy was used in 10/11 (90.9%), with meropenem (81.8%). Mortality was 18.2%; another 18.2% had severe sequelae requiring ventriculoperitoneal shunt. Unfavorable outcomes (GOS 1-3) were nominally associated with seizures, respiratory failure, hypokalemia, and lower leukocyte counts; none was significant after Bonferroni correction.Conclusion: In this multicenter series of previously unpublished pediatric cases from Türkiye, L. monocytogenes meningitis carried substantial morbidity and mortality. Early Listeria consideration in cephalosporin-unresponsive meningitis, ampicillin-based therapy, CSF PCR, and pediatric immunology referral should be considered. What is Known: • L. monocytogenes is cephalosporin-resistant; post-neonatal pediatric data are limited to small series and case reports What is New: • In 11 Turkish children, mortality and severe sequelae were each 18.2%. • One case had an ampicillin-resistant isolate; another mimicked autoimmune limbic encephalitis radiologically, illustrating diagnostic overlap. • Unfavorable outcomes (GOS 1-3) were nominally associated with seizures, respiratory failure, hypokalemia, and lower leukocyte counts;however, none remained significant after Bonferroni correction.
Indexed as
Identifiers
42570017What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.